AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Zai Lab Reports Q2 2025 Results: Revenue Grows 9% YoY, VYVGART Utilization Sets Record, and Operating Loss Improves 28% YoY.
ByAinvest
Thursday, Aug 7, 2025 6:07 am ET1min read
Zai Lab announced Q2 2025 financial results, with total revenues growing 9% YoY to $110.0 million. The company reaffirmed its full-year 2025 revenue guidance of $560 million to $590 million. VYVGART reached record patient utilization, and updated national guidelines elevated its role in treating both acute and maintenance gMG. ZL-1310 data presented at ASCO 2025 showed a 67% ORR across all doses, with a differentiated safety profile. Zai Lab is on track to achieve profitability in Q4 2025.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet